drugset / Trial / NCT04674527
Pilot Study of Elemene in Treating Patients With Refractory Glioblastoma
Phase 2
Unknown
30 enrolled
Second Affiliated Hospital, School of Medicine, Zhejiang University
Hangzhou Normal University · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a pilot phase I study to evaluate the safety and efficacy on elemene injectable emulsion in treating patients with glioblastoma. Elemene, isolated from the Chinese medicinal herb Curcuma wenyujin, was shown to exhibit antitumor activity in human and murine tumor cells in vitro and in vivo.Elemene injectable emulsion against malignant tumors was low. Therefore, the effect of Elemene injectable emulsion being used in clinical settings needs to be confirmed by further RCTs.
Timeline
- Start
- 2021-06-01
- Primary completion
- 2023-06-01
- Completion
- 2023-06-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Elemene | Traditional medicine (herbal / TCM) | 80 mg | — |
| Background | Temozolomide | Small molecule | 150 mg/m2 | — |